0000000001070565

AUTHOR

Robert Fogel

showing 1 related works from this author

Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in…

2014

BACKGROUND: To further assess the safety profile of the fixed-dose combination of indacaterol and glycopyrronium (QVA149) and its monocomponents; we investigated the impact of individual patient-level factors and time by integrating the patient-level safety data from the QVA149 clinical programme with relevant information from the independent indacaterol and glycopyrronium safety databases.METHODS: Data from 11,404 patients with chronic obstructive pulmonary disease (COPD) were pooled from 14 clinical studies of QVA149, indacaterol and glycopyrronium of ≥3 month's duration with at least two of the treatment groups: QVA149 110/50 μg, glycopyrronium 50 μg, indacaterol 150 μg, placebo or tiotr…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyFixed-dose combinationScopolamine DerivativesQuinolonesPlaceboPooled analysisPulmonary Disease Chronic ObstructiveRisk FactorsInternal medicinemedicineHumansTiotropium BromideIndacaterolAgedCOPDbusiness.industryTiotropiumHazard ratioQVA149Middle Agedmedicine.diseaseGlycopyrrolateConfidence intervalBronchodilator AgentsDrug CombinationsTreatment OutcomeAnesthesiaIndansIndacaterolDrug Therapy CombinationFemaleGlycopyrroniumSafetybusinessBody mass indexMacemedicine.drugRespiratory Medicine
researchProduct